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Abstract
Background: The Bhutanese So-wa-rig-pa medicine (BSM) was integrated with the allopathic (modern) health care
system in 1967. Ever since the health care integration policy was implemented, the BSM has gone through many
phases of quality improvement and changes including the establishment of one university-based institute, 58 hospitals
and Basic Health Units (BHU)-based health care services, and one traditional medicine factory. The BSM provides
primary health care services to more than 20–30 % of patients who visit hospitals and BHU on a daily basis. However,
there has been no study covering the quality assurance system of BSM. Our paper addresses this information gap.
Methods: This study was an observational ethnographic study supported by phenomenological understanding and
content analysis of the data. The information was triangulated through consultation with the BSM practitioners
(discussion (N = 8)) and personalized in-depth question-answer sessions using electronic protocols (N = 5). These
participants comprised BSM educationists, clinical physicians, researchers, production and the quality assurance staff
who were selected using convenience and purposive sampling method. The relevant So-wa-rig-pa information and
literature were obtained from the government policy documents, official websites, scientific papers and the traditional
medical texts. This study is enhanced by our practical observations and first-hand experience with BSM while working
as the researchers at the Ministry of Health in Bhutan. In addition, the information in this paper is crosschecked and
authenticated by five So-wa-rig-pa practitioners of Bhutan.
Results: The study highlights the following: a) The BSM receives both the government and people’s support, b) The
quality assurance system have been developed by integrating the traditional empirical knowledge and modern scientific
protocols, c) There exist three administrative and functional organizations responsible for providing the quality BSM health
care services in Bhutan, d) Extensive standard treatment guidelines and Quality documentation system exist for BSM as
required by the regulatory bodies in Bhutan. The paper also recommends appropriate future directions for BSM.
Conclusions: The BSM plays significant role in the primary health care system of the country. Consequently, the quality,
safety and efficacy of BSM has been given priority by the Bhutan government. Many scientific protocols were integrated
with the traditional quality approaches and further scientific studies are still required to improve its quality.
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services, Traditional medical education, Traditional medicine hospital, Menjong sorig pharmaceuticals
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Background
The use of traditional medicine (TM) or complementary
and alternative medicine (CAM) is widespread around the
world. It is estimated that approximately 85–90 % of the
world’s population including developed nations use trad-
itional or alternative or herbal medicines [1]. Its use is in-
creasing worldwide [2]. With the growing use of TM,
demand has grown for evidence on the quality, safety and
efficacy of TM products and practices. Even in Bhutan
with a strong history of TM, few doctors with a scientific
outlook express reservations or are skeptical about the
purported benefits of TM. Therefore, scientific validation
of TM and creation of standard research data or know-
ledge to address the issues of quality, safety and efficacy
has become a pressing issue. Creation of such scientific
knowledge can help create the basis for better health care
integration and an evidence-based health system that is
more respectful towards local practices [3] and foster bet-
ter collaborations across medical professionals.
Realizing the importance of TM, the World Health
Organization (WHO) exercised the following: a) a need for
common understanding of what constitute TM, b) the inte-
gration of TM with allopathic medicine, and c) the mea-
sures to improve the quality, safety and efficacy of TM [4].
To facilitate the development of the quality control system,
the WHO also developed general standard policies, strat-
egies, frameworks, guidelines, protocols, standard operating
procedures, regulations and bylaws [2, 4–7]. While the TM
in many countries are struggling to meet these WHO qual-
ity requirements-mainly for the lack of government’s sup-
port, the Bhutanese traditional medicine (BTM) or the
Bhutanese g.so-ba-rig-pa (pronounced as So-wa-rig-pa)
medicine (BSM) has gained roots in the mainstream health
care system of the country.
The BSM enjoyed wider people’s acceptance, received
the successive Kings’ and the government support and
was integrated with the allopathic or modern medicine
in 1967. It started with a small dispensary in 1968 and
developed into one of the complex organizations in the
country with three main BSM management sectors:
Department of Traditional Medicine Services (DTMS),
Menjong Sorig Pharmaceuticals (MSP), and the Faculty
of Traditional Medicine (FoTM). The DTMS under the
Ministry of Health (MoH), looks after one National
Traditional Medicine Hospital (NTMH), two regional
referral traditional hospitals (Monger and Gaylegphu),
17 traditional medicine hospitals and additional 38 trad-
itional medicine units established alongside major Basic
Health Units (BHU) in the country. These units treat
more than 20–30 % of the total daily out-patients visit-
ing the hospitals and other health centers on a daily
basis [8]. The MSP conducts research, quality assurance
and quality control of raw materials and manufactured
herbal products, medicinal plants collections, and
processing of traditional medicines, which are distrib-
uted freely to the traditional medical centers across the
country. The medicinal plants collection program facili-
tates the economically disadvantaged yak herders and
other farmers to earn income and elevate their socio-
economic status. It also helps in the conservation of
pristine environment and has potential to facilitate the
growth of herbal industry as well as the biodiscovery
projects based on their ethnobotanical information. The
FoTM under the Khesar Gyalpo University of Medical
Science of Bhutan (KGUMSB) trains human resources
required for catering the traditional medical services to
the people.
All these three organizations are together responsible
for the preservation of rich traditional medical culture
and in providing quality, safe and effective traditional
health care services. Ensuring the quality or ethnoquality
of the BSM has direct implications on its long-term sus-
tainability and the preservation of rich traditional med-
ical knowledge. We have coined the term ethnoquality
for the first time here and we defined it as “The cross-
cultural study of the traditional knowledge and customs
of how various ethnic healers/traditional medicine prac-
titioners perceive and monitor the quality of medicines”.
In their continuous efforts (more than 46 years) to im-
prove the ethnoquality and preserve this age-old medical
tradition, the FoTM, DTMS and MSP has undertaken
various programs, measures and strategies. However,
there is lack of proper studies or published information
on what has been done so far to improve the quality of
BSM. Not many people are aware of (including
Bhutanese) whether there exists any proper policy and
the quality management system while providing trad-
itional So-wa-rig-pa medicine in the country.
This raises many questions. Is this medical system ac-
cepted by the people as a complementary health care
system? Is it financially supported and protected by the
government to be an integral part of Bhutanese health
care system? Whether or not if there is any problem
with the quality, safety and efficacy of the So-wa-rig-pa
medicine? What are the quality assurance systems, prac-
tices and pillars that have been developed by the FoTM,
NTMH and MSP? How is the quality of traditional
So-wa-rig-pa medical education monitored and main-
tained by FoTM? How is the quality of traditional health
care services managed by the traditional medicine
hospital/units in the country? How is the quality and
safety of medicines/drugs monitored and managed by
MSP? Is there any scientific quality parameters and stan-
dards developed for assuring the quality, safety and effi-
cacy of the medicines? Is there any scientific research
carried out to make the BSM evidence-based medicine?
What are the current quality deficiencies and how can
they be addressed?
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Having these research questions answered would give
insights into the quality assurance system and the prac-
tices of an integrated health care services of Bhutan that
has potential for providing the managerial lessons for
other So-wa-rig-pa practicing countries and TM entre-
preneurs including Tibetan medicine. Therefore, this
study was conducted to determine what has been
achieved in relation to improving the quality, safety and
effectiveness of the traditional So-wa-rig-pa education,
health care services and medicine production. It also
sheds light on the existing government policies and the
regulations related to the BSM and provide future
directions.
Methods
Concepts and design
This study was derived from an on-going phenomenal
changes involving Bhutanese So-wa-rig-pa medicine
ever since its integration with the allopathic (western)
medical system in 1967. The concept was to describe,
explain and present to an international audience its
quality assurance system and practices that were either
modified in-situ based on traditional empirical know-
ledge or borrowed from western medicine quality
control systems. Thus, our study design/framework
includes ethnography, phenomenology and content
analysis. In our ethnographic approach, we have asso-
ciated ourselves as the researchers (both trained in
western education system) for more than 13 years at
the MSP and have worked closely with the Bhutanese
So-wa-rig-pa communities - mostly traditional physi-
cians at the FoTM, NTMH and MSP. These engage-
ments with the practitioners helped us gain insight
into their condition and perception of health system
while also shaping our phenomenological understating
including So-wa-rig-pa philosophy and historical
events. Our own personal experience and first-hand
observational work enabled us to compile and synthe-
sise the existing information.
This observational data was then supported by the
content analysis of the existing body of literature (both
scientific and traditional) including traditional medical
textbooks, health system policy documents, regulatory
frameworks, traditional medicine education curriculum,
disease classification and treatment guidelines, diagnos-
tic methods and treatment practice records, quality as-
surance guidelines, standard manufacturing instructions,
product profiles, medicinal plants collection reports and
other documentation practices of three organizations
(FoTM, NTMH, MSP) that were made available at the
time of study. This information sources were extracted
from the existing library, government websites, policy
documents, acts, regulations, guideline books and the
published scientific literature that are all retained in our
research notes and listed in the bibliography. Some con-
tents were obtained as previously described [8]. The
search terms such as: ‘Bhutanese So-wa-rig-pa medicine’,
‘Bhutanese traditional medicine’, ‘Bhutanese medicinal
plants’, ‘health policy’, ‘drug policy’, ‘medicine act’, ‘quality as-
surance’ and ‘quality control parameters’ were used for the
content analysis involving the internet and relevant data-
bases. For obtaining specific references and guidelines that
are used for improving the quality of health care services,
traditional medical education and the production of medi-
cines, a standard data entry form was developed and dis-
tributed to relevant study participants representing FoTM,
NTMH and MSP who were then requested to fill the form
with the latest references used at these three organizations
to guide the quality assurance practices. To clarify, cross-
check and authenticate the unstructured data that we have
observed and recorded through ethnographic and content
analysis methods, we have also consulted more than five
Drungtshos (So-wa-rig-pa medicine physician), two smen-
pas (traditional clinical assistant) and a Pharmacognosist
of MSP (see Acknowledgement for their details) (total par-
ticipant N = 8). These expert participants were selected
using convenience and purposive sampling method. They
were consulted mainly based on their vast experience in
the areas of traditional clinical practices, university lec-
tureship, herbal formulations, field identification and col-
lection of medicinal plants. The consultation with these
experts especially on the clinical, teaching and medicinal
plants identification practices were carried out using one-
one in-depth question—answer sessions either through
Facebook chat or an email correspondence. The topics of
open discussions varied depending upon our understand-
ing of the BSM practices.
The systematic process in documenting observations
and learning from the focus group discussion was
performed as previously described by Wangchuk et al.
[8, 9]. Both the qualitative and quantitative information
was gathered and retained in our research notes,
Facebook chat account and the email correspondences.
Drungtshos (N = 5) (see details in the Acknowledge-
ment) were involved to triangulate the data sources in
this paper by engaging them to proofread the manu-
script, authenticate the information and let them raise
their comments, which we have incorporated in the
paper.
Research team and reflexivity
While the first author obtained his M.Sc. and PhD
credential in medicinal/natural products chemistry from
the University of Wollongong in Australia, the second
author obtained his higher national diploma quality as-
surance certification from Hull College, UK and
postgraduate diploma in GMP from the Swinburne
University of Technology in Australia. As a Senior
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Researcher and a Quality Manager at MSP for more than
13 years, we have worked closely with the Bhutanese So-
wa-rig-pa communities - mostly traditional physicians at
the FoTM, NTMH and MSP through which the cumula-
tive information was gathered, processed and reported
here. During that timeframe we have observed, recorded,
participated in many traditional So-wa-rig-pa meetings,
conferences and group discussions, involved in translation
of So-wa-rig-pa medical uses and terms, provided train-
ings to the traditional physicians and clinical assistants on
modern research methodology, investigated many re-
search problems and even helped them devise quality as-
surance parameters to strengthen So-wa-rig-pa medical
system in Bhutan. More specifically, both the qualitative
and quantitative information was gathered using the
method as described in Wangchuk et al. [8, 9] and also
through Facebook based-chat interviews and the email
correspondences (conducted as the part of first author’s
PhD work in between 2009 and 2014). The study partici-
pants were our office colleagues working at the FoTM,
NTMH and MSP as the So-wa-rig-pa practitioners, lec-
turers, administrator, researchers and the quality special-
ist. We have avoided biasness in our reasoning and no
assumptions were made to enhance the current practices
of Bhutanese So-wa-rig-pa medicine. The study is much
of a factual description based on our ethnographic and
content analysis, which is presented as-it-is practiced in
Bhutan.
Data analysis and reporting
Ethnographic data were recorded and were authenti-
cated with the participants from FoTM, NTMH and
MSP. The content analysis was used for synthesizing the
data of oral accounts and the literature statements on
the quality policy, regulation, safety and efficacy mea-
sures. The information was then compiled and repre-
sented into diagrammatic quality pillars for each
organizations as: a) quality practices of university-based
traditional medical education (FoTM), b) quality prac-
tices of hospital-based health care services (NTMH),
and c) the quality practices of production-based medi-
cines at MSP. Our first-hand experience as the re-
searchers with the BSM for more than 13 years
enhanced the data analysis, synthesis and discussions of
this paper.
Study limitations
This study did not cover the patients’ perspectives or
that of policy and decision makers at the Ministry of
Health in Bhutan. It is purely an observational and con-
tent analysis study and is designed to present the quality
assurance system that is in practice at FoTM, DTMS
and MSP at the time of study. A separate cross-sectional
study is necessary to understand the patients' or general
public’s perspectives on the quality of BSM.
Results and discussions
The series of information obtained through appropriate
ethnographic observation, content analysis, open forum
discussions, social media interviews (Facebook and
emails) and proofreading process were analysed,
triangulated and presented here mostly in a descriptive
manner under five different categorical sub-titles. They
are: a) Policy frameworks supporting the Bhutanese
So-wa-rig-pa health care system, b) Quality assurance
system and practices of the Bhutanese So-wa-rig-pa
medicine, c) Hospitals/health centers-based quality as-
surance of BSM health care services, d) University-
based quality assurance of BSM education and human
resource development, and e) Pharmaceutical industry-
based quality assurance of medicine productions.
Wherever relevant, the important policies and informa-
tion has been quoted to stress the importance given by
the government in Bhutan. Also relevant quality assur-
ance documents from the WHO has been used as the
standards to compare the quality parameters set by
MSP during the manufacturing of traditional So-wa-
rig-pa medicines. The triangulation of these data
further helped us generate diagrams to illustrate our
observations and also to formulate constraints, chal-
lenges and suggestions, which we described in details
that follow.
Policy frameworks supporting the Bhutanese So-wa-rig-pa
health care system
The content analysis revealed that even before the
WHO policy of integration was formulated, the third
King of Bhutan, Jigme Dorji Wangchuk integrated the
BSM with allopathic medicine as early as 1967. During
our 13 years of observations, we saw the BSM being
transformed into a sophisticated organization. For exam-
ples, the small training institute was being upgraded to
FoTM under Khesar Gyalpo University of Medical
Sciences, the NTMH was upgraded to the Department
of Traditional Medicine, and the small Research and
Quality Control Laboratory (RQCL) was upgraded to
semi-mechanized MSP. Today, there are 58 traditional
medical hospitals and units, which are established next
to each modern hospital building, follows the main-
stream medicine acts and regulations, and adheres to in-
tegrated policy of quality assurance system. The BSM
has become one of the important cultural and traditional
heritages of Bhutan and there are proper inspection and
enforcement agencies to check if the quality of BSM is
practiced at the acceptable level within Bhutan. This
medical system is enshrined in the constitution [10] and
it is stated that ‘The State shall endeavor to preserve,
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protect and promote the cultural heritage of the country’
and ‘shall provide free access to basic public health ser-
vices in both modern and traditional medicines’. Bhutan
2020: A Vision for Peace, Prosperity and Happiness [11]
states that, ‘We must continue to provide a place for
traditional medicine in our system of health care and
must seek to achieve further improvements in its quality.
As these qualities become substantiated by scientific re-
search, there is a growing need to integrate traditional
medicine more effectively with the modern health care
system’. The national health policy of the Ministry of
Health [12] states that, ‘Focused efforts shall be directed
towards making the BSM, the center of excellence in
providing quality traditional medical services including
wellness center that is recognizable at an international
level’. The National Drug Policy [13], states that ‘The
government shall promote and support research and
local manufacture of pharmaceuticals including trad-
itional medicines and that the Drug Regulatory Author-
ity (DRA) shall be the agency that develops and
implements most of the legislation and regulations
related to quality, safety and efficacy of drugs and the
accuracy of product information on pharmaceuticals’.
The Medicines Act of the Kingdom of Bhutan [14] and
Bhutan Medicine Rules and Regulation [15] mentions
that ‘The pharmaceutical factories including the MSP
should conform to the current Pharmaceutical Inspec-
tion Convention/Co-operation Scheme (PIC/S) Guide to
Good Manufacturing Practice (GMP) for medicinal
products, shall have a separate quality control unit with
qualified staff and appropriate equipment to carry out
quality tests of raw materials and the finished products,
and shall register the medicinal products with the DRA
of Bhutan prior to making commercially available in the
market’. The Quality Assurance and Standardization
Division (QASD) [16] states that ‘QASD shall support
the process of continuous quality improvement through
policy development and adoption, establishment of qual-
ity standards, training and implementation of quality
strategies at health facility and health program levels.’
Bhutan Medical and Health Council (BMHC) mandate
states that ‘The medical and health professionals should
be all registered to promote competency and ensure the
safety of health of the public’.
While the DRA and the BMHC are the independent
external regulatory bodies that frame overall laws and
regulate the quality of the medicines and services, the
QASD is an internal body under the Ministry of Health
which monitors and assess the quality of services and
prepares the organizations for compliance to external
regulatory requirements. Most of these policy frame-
works, regulatory statements and the quality parameters
are found accommodative of BSM concepts and require-
ments. This is a strong indication of the government
support on the preservation, growth and promotion of
BSM as a health care provider. The BSM, which is based
on Buddhist philosophy, has strong quality and moral
ethics, health concepts and manufacturing process,
which can enrich the western-borrowed health quality
concepts and parameters.
Quality assurance system and practices of the Bhutanese
So-wa-rig-pa medicine
We have observed that the BSM has made decent pro-
gress in all areas of infrastructure, human resources and
quality assurance system ever since its integration with
allopathic/modern medicine in 1967. Traditionally, ac-
cording to Drungtsho participants, the quality of BSM is
defined by smen-pai-ju-druug (Physician’s six merit/cri-
teria) and che-pai-yen-lag-b.duen (translated as ‘seven
quality attributes of medicinal procedures’ or ‘seven af-
fectionate branches of medical practices’). In essence,
the quality of BSM is determined by how the diseases
are diagnosed appropriately through compassionate
patient-centered approach by the physicians and facili-
tates development of the patient’s balanced health -
physically, mentally and spiritually. According to WHO
[17], the quality of a health system is defined as a
process of seeking continuous improvements in the
dimensions of acceptability, accessibility, equitability,
efficiency, effectiveness, and safety. This study reveals
that, the MoH have continuously strived to improve
these six dimensions of quality in BSM through
three main administrative and functional strategies: a)
imparting quality BSM education and developing
technically qualified and skilled practitioners at FoTM,
b) establishing BSM hospitals alongside all modern
hospitals and BHUs and providing free health care
services throughout the country, and c) manufacturing
quality medicines at MSP using pristine Himalayan
medicinal resources.
University-based quality assurance of BSM education and
human resource development
Most of the participants who contributed and authenti-
cated the information in this study were the alumni of
FoTM (previously known as NITM). The documents
and the websites of FoTM highlighted the institute being
a premier tertiary institute in the country (with more
than 48 years of experience) in providing quality BSM
education. Its vision and mission [18] states that: ‘The
FoTM will strive to achieve excellence in the design, de-
velopment and delivery of So-wa-rig-pa education pro-
grams through research and innovation, blending rich
ancient wisdom and modern science to make the pro-
grams relevant for the current health needs of the
people. It will incorporate the values and principles of
Gross National Happiness (GNH) as foundation for all
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educational programs and will aspire to enhance their
quality through realization of the core values including
love and compassion to patients, research and develop-
ment and integrated approach to health care’. The con-
tent analysis of literature related to FoTM revealed that
the FoTM has come a long way in terms of infrastruc-
ture development and the way the education has been
imparted to students. The first Indigenous Training
Centre was established at Dechencholing, Thimphu
where eight students underwent three years smen-pa
(diploma) courses and in 1978, five years Drungtsho
(Bachelor of Science in Traditional Medicine) course
was instituted under the Ministry of Health (MoH).
Through interactions with Drungtshos and other BSM
colleagues, we found that the first batch of students were
recruited from among the Buddhist monks, Gomchens
(lay priest), sons or daughters or relatives of already
practicing Drungtshos, and the Semtokha school gradu-
ates of Institute of Language and Cultural Studies
(ILCS). Quality of education, knowledge and practice
varied from a teacher to teacher (determined by a
lineage based practices) and also among the students.
We observed that students whose parents were them-
selves So-wa-rig-pa practitioners enjoyed best status and
earned more respect. Since the lecturers who were first
recruited to teach the students at the NITM (now called
FoTM) had their training and education from different
masters and traditional medical institutes in Bhutan and
Tibet, inconsistencies and discrepancies–mainly in se-
cret Tantra knowledge and identification of medicinal
plants–were more prevalent until mid-1980s. These
problems appeared to have resolved by 1988 through the
standardization of BSM knowledge, curriculum, peda-
gogy and introduction of botanical identification system.
We have triangulated the data sources and standardized
both traditional and botanical nomenclature of medi-
cinal plants nomenclature as described by Wangchuk et
al. [9]. The curriculum and duration for the B.Sc. in TM
course was set for five years with additional six months
of internship to maintain equivalence to the allopathic
system of Bachelor of Medicine and Bachelor of Surgery
(MBBS) courses.
Historical accounts have it that, in an effort to
modernize and transform So-wa-rig-pa medicine into a
scientifically-validated evidence-based medicine, the
MoH recruited Dr. Paolo Morisco (Western Medical
Doctor) to establish the Research and Quality Control
Laboratory (RQCL) in 1990 with the help of an Italian
Disarmo Sviluppo (DISVI) project. Through this project
and under his technical expertise, Research Assistants
were trained for three years at the NITM. To train the
local students and scientifically validate the BSM, he
further recruited other technical experts with multi-
disciplinary qualifications in the areas of ethnobotany,
pharmacy, pharmacognosy, chemistry, pharmacology
and herbalism. The quality of education provided by the
NITM was strengthened when it became a part of the
Royal University of Bhutan (RUB) in 2003. Various
changes, including the curriculum, were implemented in
accordance to the requirements of the RUB system and
guidelines [19]. The establishment of the ‘Traditional
Medicine Research and Development Committee of
Bhutan’ (TMRDCB) and the introduction of the
‘Menjong Sorig Journal’ (MSJ) in 2008 improved the
quality of research that were carried out at NITM and
the quality of research papers that were published in the
journal. The first author of this paper (Phurpa
Wangchuk), Drungtsho Tempa Gyeltehen and Dorji
Wangchuk (NITM director) initiated the development
of TMRDCB and MSJ and coordinated the research
meetings and the publications of journal issues on an
annual basis. The NITM and the Royal Institute of
Health Sciences (RIHS) were formally transferred to the
newly established University of Medical Sciences of
Bhutan (UMSB) in 2013, which was in 2015 renamed as
the Khesar Gyalpo University of Medical Sciences of
Bhutan (KGUMSB). Today, it functions as the Faculty of
Traditional Medicine (FoTM). A participant from FoTM
stated that, ‘the FoTM now has separate newly con-
structed state-of-the-art administrative and academic
block with built-in library facilities; a computer labora-
tory with Wi-Fi internet connections; modern lecture
rooms equipped with liquid-crystal display projectors; a
demonstration laboratory with facilities and dummies to
learn human anatomy; and the traditional equipment for
medicinal preparations. It follows the medical university
policies, directives, education guidelines and the curricu-
lum, which is revised every five years’. Our analysis of
the FoTM textbooks, documents and curriculum re-
vealed that there are about 28 traditional textbooks,
which are used as the key teaching and learning re-
sources – the main being Gyud-zhi (Four Medical
Tantras) and Shel-gong-Shel-phreng (The Crystal Mirror
and Rosary). The FoTM lecturer have adopted more
progressive educational pedagogical methods including
question-answer sessions, presentations, project-based
learning, demonstrations, clinical assessments, spot
identification, interacting with dummies, and field work
training. The quality of the academic sessions also im-
proved with the introduction of modern learning mod-
ules in addition to the traditional classical So-wa-rig-pa
modules. The five-year academic program for Drungt-
sho course has a total of 49 modules with 660 credit
hours out of which 39 modules are on So-wa-rig-pa
medicine [20] and the remaining ten modules include
research methodology, English language, information
and communication technology, universal human
values and professional ethics, analytical skill, modern
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anatomy and physiology, hospital management and
sanitation, and the national health care system. The
three-year smen-pa course has a total of 28 modules
and 360 credit hours [21] with 21 core modules on gen-
eral So-wa-rig-pa. ‘The Medical and Health Council
Act’ [22], ‘Royal Government of Bhutan Medical and
Health Council’ [23], and the ‘Disciplinary Proceedings
for Medical Malpractice and Negligence Regulations’
[24] made it mandatory for the passing out graduates
from FoTM to register themselves and obtain clearance
for clinical practices and refrain from malpractices that
would risk the safety of patients. The current FoTM
practices, although not stated in the RUB norms, falls
under the eight pillars/categories of quality assurance
strategies as shown in Fig. 1.
These sets of FoTM’s practices resulted in producing
high-quality graduates that have even surpassed other
technical graduates from other modern technical univer-
sities both within the country as well as from abroad.
These changes had ripple effects in quality of BSM edu-
cation and students. For examples, in between 2007 and
2013, two FoTM graduates topped the Royal Civil Ser-
vice (RCSC) examination [25] and all the graduates
secured government job which were indicative of the
quality of BSM education policy and courses offered by
the institute. Getting selected in this RCSC examination
is considered the stepping-stone to higher echelon of
professional and leadership career in the country.
Hospitals/health centers-based quality assurance of BSM
health care services
To the best of our knowledge, there exist no specific pol-
icy or NTMH statement that mentions the need to adhere
to the WHO definition of quality while providing trad-
itional health care services. However, we have observed
that the DTMS under the MoH have strived hard to ad-
dress and attain many dimensions of quality, which we
have depicted in Fig. 2 as the eight dimensions of quality
pillars that are in a way related to the WHO definition of
the quality of a health system. The WHO dimensions of
quality of health care system includes achieving accept-
ability, accessibility, equitability, efficiency, effectiveness,
and safety. Since BSM is closely knitted with Buddhism
that is central to people’s beliefs, cultures and tradition, it
has gained widespread acceptance from the king, govern-
ment and the people. The Buddhist-based ethical
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Fig. 1 Eight pillars or strategies of quality assurance system practiced at FoTM in providing BSM education and training
Wangchuk and Tashi BMC Complementary and Alternative Medicine  (2016) 16:283 Page 7 of 18
principles and modern clinical norms practiced by the
Drungtshos have also helped gain respect for the medical
system. A study conducted in Thimphu by Lhamo and
Nebel [26] showed that the attitude of people towards
BSM was still good and encouraging, and that the treat-
ment is sought by all ages, young and old and also across
different levels of education. The practitioners themselves
believe that BSM is a patient-centred health care delivery
system where all patients are provided free access to it
ever since its integration with modern health care system.
Having the BSM alongside modern hospitals not only
provided health care choices and access from the same
building to the people but also helped preserve one of the
country’s rich cultural heritages.
So-wa-rig-pa medicine dispensary was established at
Dechencholing in 1968 and since then the government
has expanded the services to all parts of the country
with the objectives of making it more accessible. Cur-
rently, we found that there are 58 BSM centers/units at-
tached to modern hospitals and Basic Health Units
(BHU), which are distributed equitability in all parts of
the country. The health care integration policy enabled
the BSM to share the modern hospital building and
other health resources that expedited the establishment
of the traditional treatment centers in a cost effective
manner. Accommodating both modern and BSM in the
same hospital have maximized resource utilization and
facilitated efficient cross referral of patients between the
two medical systems. Drungtshos and smen-pas, with
whom the authors have consulted and worked with for
more than 13 years, said that modern doctors often refer
to them the patients with chronic diseases such as
sinusitis, arthritis, rheumatism, digestive and nervous
disorder. On the other hand, the Drungtshos refer the
patients that require surgeries and antibiotic treatment
to modern doctors. The BSM has niche health care ser-
vices including preventative care that focuses on lifestyle
or behavioral adaptations. Lifestyle changes involve per-
sonal adaptations to the ever changing seasons, climates,
environment, diets and other societal norms. The infor-
mation on lifestyle changes also forms part of the daily
prescription advice and counseling services provided by
Good dispensing 
practices and 
managing 
adverse drug 
reaction for 
safety 
Following 
standard 
procedures, 
treatment and 
therapy 
guidelines 
Providing free 
health care 
services for equal 
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medicine 
distribution for 
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Monitoring and 
inspecting the 
health service 
system by QASD 
of MoH for 
effectiveness 
Establishing 
traditional 
medicine units 
countrywide for 
people’s 
accessibility
Standard codes of 
diseases, service 
delivery and 
treatment 
practices
Good clinical 
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teaching to 
enhance people’s 
acceptability
Quality pillars 
of BTM health 
care services/ 
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system
Fig. 2 Eight pillars of hospital-based quality practices of BSM in Bhutan
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the physicians. Mental health and general wellness activ-
ities have already been explored by the DTMS, MoH in
Bhutan. The BSM treatments have improved the health
outcomes for many individuals and communities. How-
ever, the treatments provided by BSM practitioners
varied among the individual Drungtshos and smen-pas
depending upon their knowledge and experience.
So-wa-rig-pa medicines are generally considered safe,
but like modern drugs it can result in overdose and se-
vere side effects if patients fail to adhere to the prescrip-
tion advice and counseling provided by the physician.
Overdose and poisoning is also more likely to occur
when the physicians or clinical assistants lack clinical
experience. To detect, report and manage these adverse
drug reactions and side effects, a Pharmacovigilance
Center or the Adverse Drug Reaction Surveillance and
Reporting System (ADRSRS) was established at MSP in
2007 (later transferred to NTMH). It is also a norm to
report such incidents directly to the Post Marketing
Surveillance Division (PMSD) and the Drug Regulatory
Authority of Bhutan (DRAB). In addition, we found that
numerous standard guidelines and reference materials
were developed by NTMH through series of consultative
workshops to provide BSM treatments with same qual-
ity, safety and effectiveness. Our analysis of the existing
documents, guidelines and reference materials of the
NTMH revealed that seven of them were guidelines that
help BSM practitioners in providing quality, safe and
standard health care services. They are:
i. Traditional classification of diseases and related
health problems-2005 [27]. About 79 diseases that
are prevalent in Bhutan are described, coded and
standardized by this guidebook and helps the BSM
practitioners in correct diagnosis and proper
treatments.
ii. Standard treatment guide for traditional medicine-
2006 [28].
iii. National traditional medicine professional service
standards-2007 [29].
iv. Guidelines for detecting, reporting and managing
adverse drug reaction-2007 [30].
v. Therapy guidelines for traditional medicine
practitioners-2008 [31].
vi. Standard operating procedure for traditional
medicine services-2008 [32].
vii.Monographs on the use of traditional medicine in
primary health care-2012 [33].
These guidelines form the part of the continuing med-
ical education (CME). The Drungtshos and smen-pas are
trained on how to follow, operate and use these guide-
lines while providing the traditional medical health care
services.
Pharmaceutical industry-based quality assurance of
medicine production
Traditionally, the quality, safety, and effectiveness of any
medicine/drug is believed to be determined by the qual-
ity of the raw materials and how they are handled
through collection and production processes. Like mod-
ern medicine, the quality assurance of BSM production
is very complex. What makes it even more complex is
its multi-ingredient formulations. Some BSM has more
than 100 ingredients with each ingredient possessing as-
sembly of complex chemicals. Hence determining purity
or impurity profiles for BSM formulations is harder to
achieve. It requires cross-disciplinary approach and ex-
tensive collaborations with many stakeholders including:
farmers, raw material suppliers, traders and business-
men, farmers, park managers, foresters, conservationist,
environmentalist, ecologist, horticulturist, Drungtshos,
smen-pas, chemist, pharmacognosist, pharmacist,
pharmacologist, ethnobotanist, quality control manager,
drug regulatory inspectors, planners and administrators.
Besides, it requires careful approach to see that while
modern scientific quality control protocols are intro-
duced, the ancient wisdom of BSM is not lost or dis-
carded. Therefore, it is apparent that huge financial
resources is required to establish and run the mecha-
nized BSM factory that is accommodative of both mod-
ern standards and empirical traditional practices.
From historical accounts of MSP, we found that be-
tween 1980s and 1990s, numerous international funding
bodies including World Health Organization (WHO),
Italian DISVI project, non-governmental organization
and two successive European Union (EU) projects
(Phase I in 1994–1998; Phase II in 2006–2009) were
brought in to establish the MSP with modern infrastruc-
ture, mechanize the medicine production, strengthen
human resource capacity, conceptualize corporatization
of MSP and address the long term sustainable supplies
of traditional medicines. Under these projects, various
technical experts/assistants (TAs) from Europe, India
and Thailand have been recruited in Bhutan and their
technical inputs can be observed in the current MSP in-
frastructures, research activity settings, quality control
system, Good Manufacturing Practices (GMP) and Good
Laboratory Practices (GLP). While modern scientific
approaches including the Good Manufacturing Practices
(GMP), Good Laboratory Practices (GLP), Good
Collection Practices (GCP), Good Dispensing Practices
(GDP), and the Total Quality Control System (TQCS)
were introduced, the ancient ethnoquality practices
were retained, preserved or slightly adapted to meet
the current needs.
Based on the information gathered during this study
and also observed by the authors while working at MSP
in between 1999 and 2014, it is evident that the MSP
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have capitalized on improving the eight pillars of quality
assurance norms or practices while manufacturing the
traditional medicines (as shown in Fig. 3). Our assess-
ment found that the quality of the manufactured medi-
cines has been monitored in three main tiers at MSP.
They are a) quality assurance in the field during the col-
lection of medicinal plants, b) laboratory-based quality
control testing of raw materials, pre-processed materials
and manufactured herbal products, and c) quality con-
trol of labels and packaging materials. The raw materials
include plants (as bulk ingredients), minerals, precious
metals and animal parts.
Field-based quality control of the collection of medicinal
plants
Collection of medicinal plants is the important activity
of MSP. Correct identification of plants from the fields
and the markets is considered the first crucial stage in
assuring the quality, safety, and efficacy of medicines [9].
The field-based quality control protocol was reported
previously [8]. In BSM, there exist an ancient written
code of conduct or doctrine called g.ches-pai-yan-lag-
b.dun (can be translated as ‘seven quality attributes of
medicinal procedures’ or ‘seven affectionate branches of
quality practices’), which ensure the quality of medicinal
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Fig. 3 Eight pillars or strategies of quality assurance system practiced at MSP in manufacturing BSM
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plants while collecting in the field. These seven quality
doctrines include: a) correct identification of medicinal
plants, b) collecting medicinal plants from the right nat-
ural habitat, c) following appropriate collection season
and time, d) processing, drying, pre-processing and de-
toxifying the plants (wherever prescribed), e) using appro-
priate BSM recommended drying methods, f ) proper
storage and g) spiritual empowerment of herbs. The eth-
noquality doctrine resembles ‘Good Collection Practices
(GCP). During the collection season, the farmers’ respon-
sibility is to collect the plant materials from the field based
on the prior plant collection training they have received
and the list provided to them by MSP. Other important
post harvest care (as prescribed in the traditional medical
texts), storage and spiritual empowerment are carried
out by the MSP field-work team comprising phar-
macy assistants, quality control staff and a smen-pa.
Although detoxification of plants should be done
during the fieldwork, they are currently carried out in
the MSP because of lack of adequate facilities in the
fields.
Laboratory-based quality control of raw materials
This field quality control system of the medicinal plants
is supported by the laboratory-based scientific pharma-
cognostical and the phytochemical studies. In the con-
text of quality-setting studies carried out at MSP,
pharmacognostical studies mainly involve retention of
herbarium specimen of each plant collected from the
field for authentication, setting reproducible in house
quality control standards and parameters for these medi-
cinal plants, and developing plant monograph. Our
literature search revealed that the WHO had released a
series of plant monographs [6, 34–37] containing stan-
dardized methods, limits and other quality control pa-
rameters. However, our assessment of these documents
showed that only few low altitude medicinal plants spe-
cies have been covered by these WHO monographs and
none of the 116 high altitude medicinal plants that are
currently used in BSM were incorporated. Some of the
quality parameters described in this monographs are be-
yond the affordability of many developing nations and
are also very lengthy process, which is not feasible when
hundreds of plants have to be screened for quality. As a
result, an in-house quality control standards and param-
eters were developed by MSP, with the help of the
chemist and pharmacognosist, for some high altitude
medicinal plants (HAMP) following the formats and
quality control protocols set by WHO [5, 38]. The MSP
have later compiled two volumes of monographs on 40
HAMP [39, 40] and a Handbook on Quality Control of
Raw Materials [41]. These monographs and quality con-
trol handbook are currently used as the standard refer-
ences for the laboratory quality analysis of raw materials.
The quality parameters included in those reference
books includes the following: a) macroscopical examin-
ation and organoleptic characteristics, b) microscopical
and cellular analysis (not practiced currently in routine
QC at MSP), c) foreign matter, d) essential oil content,
e) loss on drying, f ) moisture content by azeotropic dis-
tillation, g) physio-chemical analysis, h) Thin layer chro-
matography (TLC) fingerprinting and i) pH. The physio-
chemical analysis includes the determination of percent-
age values of: total ash, acid insoluble ash, water soluble
ash, alcohol soluble and water soluble extractives. The
TLC is a good quality profiling method as it portrays
unique signature of individual plants for their identifica-
tion but it is considered expensive for analyzing bulk
samples.
Although more advanced equipment such as High
Performance Liquid Chromatography (HPLC) and
Ultraviolet (UV) spectrophotometer had been installed
at MSP through European Union project assistance,
they were found underutilised for monitoring the
quality of medicinal plants and finished products due
to high running cost and complex multiple ingredients
especially in finished products. Recently, additional
high-tech equipment called High Performance Thin
Layer Chromatography (HPTLC) has been acquired
and is under heavy utilization. This HPTLC is a power-
ful, fast and cheaper tool for metabolite fingerprinting
(Fig. 4) and in analysing the quality of both plant and
finished product samples. It is widely used across the
globe in quality analysis of herbal traditional medicines
and is the most appropriate and preferred analytical
technology for complex mixtures of unknown thera-
peutic agents.
Although there is lack of research and development
facilities at MSP to carry out advance molecular, phyto-
chemical and pharmacological studies, the first author of
this paper carried out few studies to scientifically valid-
ate the ethnopharmacological uses of BSM medicinal
plants in collaboration with the University of Wollon-
gong and James Cook University in Australia, and Srina-
kharonwirot University (SU) and BIOTEC in Thailand in
between 2002–2004 and then in 2010–2014. These col-
laborative projects achieved three objectives: a) identified
the marker chemical compounds of the plants which is
used for developing monograph and quality control pa-
rameters b) validated the claims of the BSM uses of the
plants providing scientific basis, and c) discovered new
drug lead compounds. These scientific studies also re-
vealed that out of 229 species of medicinal plants cur-
rently in use at MSP for manufacturing different
polyingredient formulations, 55 species were endemic to
the Himalayas and 33 of them were never studied before
[42]. Out of 33 Himalayan species that were not stud-
ied, 10 species: Aconitum orochryseum [43, 44], A.
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laciniatum [45], Ajania nubigena [46], Codonopsis
bhutanica [42], Corydalis callaintha [47], C. crispa
[48], C. dubia [49], Meconopsis simplicifolia [50],
Pleurospermum amabile [51, 52], Ranunculus brother-
usi [53] and Tribulus terristris [53], were studied by
the first author for their phytochemical and pharma-
cological activities employing the ethnodirected, biora-
tional, and bioassay-guided strategies and protocols over a
period of six years. These scientific data aided develop-
ment of monograph and quality control parameters for
the studied species of medicinal plants.
Laboratory and GMP-based quality control of manufactured
products
Assessment of the formulary book [54] showed more
than 100 polyingredient-finished product formulations
are being described. However, only 94 of them are in-
cluded in the current Essential Drug List (EDL) of Trad-
itional Medicines that is being reviewed every after three
years by the DTMS (MoH) based on the morbidity pat-
tern and emerging need. The EDL committee members
review the list of drugs that are in use in the hospitals
and BHUs after collecting necessary feedback from the
traditional clinicians across the country. Our analysis of the
list of medicines that are manufactured at MSP showed that
the main dosage forms includes pills (30.76 %), tablets
(27.88 %), capsules (21.15 %), powders (10.57 %), ointments
(4.80 %), syrups (1.92 %) and others (4.80 %).
Our observation was that MSP initially followed the
European GMP model. Recently, the MSP has adopted
the national GMP standard based on the Pharmaceuticals
Inspections Cooperation Scheme (PIC/S). Traditionally,
each polyingredient finished product contain mixture of
different components in definitive ratios and therefore,
the quality has to be evaluated with an understanding of
the complexity of the raw materials used. Drungtshos and
smen-pas believe that diseases are treated with complex
mixtures of medicines since diseases are the expression
of/disruption of the balance of five cosmo-physical ele-
ments (wind, fire, water, earth and space). Even the medi-
cines are the expression of these five elements and the
delicate balancing of these elements creates what is toxic,
what is medicinal and which plants are of high grade or
quality. A special feature of BSM medicinal products, as
asserted by BSM practitioners, is that it is a multi-
component system containing: a) pharmacologically
active substances, b) compounds which by themselves
are not pharmacologically active but influence the
biological effectiveness of active substances, c) neutral
agents that serves as vehicle or acts as neutralizers of
the toxic matters. Therefore, the advantage of using
the multicomponent products is that the synergism
among the active and non-active principles makes the
medicine more powerful potions to treat complex
diseases.
Given the intricate BSM paradigm and multifaceted
polyingredient formulations, strictly assessing their inter-
actions, synergism and antagonism among constituent
mixtures have been always challenging. Until now, the
quality control of finished products depended heavily on
assessing their organoleptic and physiochemical proper-
ties and very little was done to explain the mode and
mechanism of action of BSM drugs. However, actions
were being taken by MSP to lay down methods,
Track Plate No:11
Visualization: UV 366nm
T1= dre-b.zang (Test sample)
T2 = dre-b.zang (Reference sample)
Visualisation: White Light
T3 = dre-b.zang (Test sample)
T4 = dre-b.zang (Reference sample)
Mobile phase: Ethyl acetate/Iso-
propanol/water (65:25:10 V/V)
T1         T2              T3          T4
Fig. 4 HPTLC profile plate developed by MSP quality control section for raw materials. T2 and T4 are the metabolite profile of reference samples
from previous batch of raw materials (stored as reference drug). When the metabolite spots observed in the test sample conforms to that of the
reference sample as observed in Track Plate No:11 (developed for dre-b.zang or Safflower in English), the test sample passes its identity test. The
presence of adulterant should show different profile to the reference drug
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standards and parameters for quality control of BSM
manufactured products/drugs and even the manufac-
tured product monograph has been developed. Quality
standard of individual finished product is prescribed in
this finished product monograph. Some general methods
and reference points used in the finished products
monograph are adopted from the British Pharmacopoeia
[55] and the internally established standards. Once the
final product, which is manufactured through series of
steps in the production section, reaches the manufac-
tured product quarantine, the quality control technicians
test them for an overall quality following the prescribed
quality control parameters in the product monograph.
The quality parameters used for screening the quality of
the manufactured products includes: a) description and
organoleptic characteristics, b) hardness, c) friability, d)
thickness, e) extractive value, f ) uniformity of weight/
dosage/weight per mL, g) pH value, h) disintegration, i)
percentage loss on drying, j) bulk density, k) dosage
forms and product identity, l) diameter m) thickness,
and the o) HPTLC profile (Fig. 5). Quality control of
label and packaging materials (includes dimensions,
GSM, design, visual effect and defect and print quality)
are also carried out to ensure their compatibility for
packaging of manufactured product. The technical staffs
responsible for the labeling and packaging section of
MSP are required to sit for competency examination
conducted by the DRAB. If the product fulfills the qual-
ity screening standards prescribed in the individual
monograph, the products passes the quality test and are
released to the Ministry of Health who distributes them
to BSM hospitals and the BSM units across the country.
However, if the final products don’t meet the quality re-
quirements prescribed in the monograph, they are either
sent back for re-processing or rejected. Rejection of a
manufactured drug is very expensive when produced in
bulk as one product contain many expensive ingredients
and therefore, all preventative in-process controls during
the production are mandatory.
The medicines that are manufactured at MSP for the
first time and are used for treating the diseases must be
registered with DRA. The DRA regulations including the
‘Bhutan medicine rules and regulations-2012’[15] and
the ‘Guideline for application for registration of medi-
cinal products-2013’ [56] states that all the finished
products or BSM drugs must produce enough dossiers/
documentations to prove their quality, safety and effi-
cacy before releasing them into the hospitals and BHUs.
Gathering the existing documents in this regards, we
found that there exist heaps of products registration
documents which include: a) company profile, b) manu-
facturing license, c) product profile, d) quality profile,
and e) guidance of documentation system. The company
profile documentation comprises an organization chart,
vision and mission statement, quality policy of an
organization, overall list of human resources, list of
qualified technical persons, types of medicines produced,
capacity of production, list of available pharmaceutical
machineries, list of quality control instruments, and the
list of key competent persons in the production and the
quality control. The product profile for each medicine
submitted for registration must have the information in-
cluding: batch manufacturing formula, list of raw mate-
rials, product name, batch size, dosage form, pack size,
manufacturing instruction, in-process quality control
procedures, list of ingredients, a copy of original So-wa-
rig-pa text references for each ingredient, a copy of
original So-wa-rig-pa text references of the finished
product formulary, manufacturing process flow chart,
pre-processing method of raw materials, labelling and
packaging instruction, and the price structure. The
quality profile includes: certificates of analysis (CoA) of
Tracks of Plate No: 10
Visualization : UV 366nm
T1 =’ba-sam-lha-lung (Reference sample)
T2 =’ba-sam-lha-lung (Test sample)
T3 = a-ru-10 (Reference sample)
T4 = a-ru-10 (Test sample)
Mobile phase: Toluene/Ethyl acetate/Formic acid 
(9:9:2 V/V)
T1      T2     T3    T4         
Fig. 5 HPTLC profile of two finished products-ba-sam-lha-lung (T2) and a-ru-10 (T4). T1 and T3 are the reference samples from previous batch
that passed the quality and has been retained as standards. When the profile of the test sample is similar to that of reference sample in terms of
number of bands, colour, size, and Rf values as in the Track Plate No:10 above, the test sample passes QC test for its identity test
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raw materials, CoA of manufactured products, CoA of
labelling, CoA of packaging, stability study report (both
accelerated and real time), adverse drug reaction report-
ing protocol, QC methods, QC release procedures and
the stability protocols. These CoAs and protocols are to
be appended with products specifications, inserts and
product samples.
Documentation system consists of three components
a) product profile which defines description, strength,
reference method, packaging type and dosage form, b)
quality profile defines manufacturing process, list of
equipment both in production and quality control la-
boratory, content of active ingredients in the manufac-
tured products, official methods used, report of raw
materials and test methods, labels and packaging ma-
terial, c) pharmacology profile is currently limited to
the traditional uses only and supplying the BSM litera-
tures as references or as supporting documents suffices
the legal requirement for this profile. Although these
regulatory requirements are mostly based on the
western-borrowed pharmaceutical concepts that are
very often difficult to fulfil, it improved the systematic
documentation system of the BSM manufacturing
process and enhanced the overall quality of the
medicines.
Constraints, challenges and suggestions
We have observed that the quality assurance system of
BSM have drastically improved in comparison to the day
when it was first integrated with the modern health care
system in Bhutan in 1967. Quality assurances have be-
come part of the good governance system and all three
organisations (FoTM, DTMS and MSP) try to constantly
adjust to the current needs of the society in the country.
There are also many health and drug related regulations
and enforcement agencies to inspect and monitor the
ethical practices of the practitioners, hospitals and
manufacturer. However, despite many improvements
and system in place, there are various issues confronting
the quality of BSM and the triangulation of data ob-
tained from content analysis, observations and open
group discussions confirmed this. The FoTM lacks
qualified and experienced lecturer who could conduct
independent inquiry-based research on BSM. Research is
a building block of any university or institution and for
FoTM, it is even more crucial to have research compo-
nent built in the curriculum. Without research compo-
nent, both the lecturers and the students would be
learning only what is being written in the ancient text-
books. These written concepts need validation through
research, which would lead to the development of
new knowledge. The KGUMSB, with new leadership, is
expected to remodel FoTM into a research-based
institute.
The DTMS has established a research section but
there is need for qualified staff to lead the section. There
are 58 BSM centres/units in total and few of these units’
lack Drungtshos. To provide quality and safe services,
qualified and competent professionals must run all these
units in the country. Therefore, there is need for more
Drungtshos. In addition, Drungtshos and smen-pas have
raised the issues of the shortage of medicine supply in
their units. The short supply of required medicine can
affect the quality of traditional health care services.
While many standard treatment guidelines and standard
operating procedures (SOPs) have been endorsed and
implemented, there is concern that few freshly appointed
Drungtshos and smen-pas lack confidence to deliver the
standard services. The training on using guidelines and
SOPs are conducted as a part of in-service CME. Instead
of having the course as a CME component, it would be
worthwhile to put them as a part of FoTM curriculum.
MSP is the nerve-centre of BSM and any shortfalls in
the medicine productions would immobilise the whole
traditional medical system of a country. Sometime the
product fails to meet the quality standard and re-
processing the formulation prolongs the release of the
manufactured products on time. The content analysis
showed that Lingzhi (in the North) and Langthel (in the
central parts of Bhutan) have been the collection centres
for medicinal plants in Bhutan for more than 48 years.
Triangulating the information collected, we realised that
there is need to establish new collection centres across the
country to meet the demand for medicinal plants. This
would not only improve the sustainability of medicinal
plants supply to MSP but doing this would also ease the
pressure on medicinal plants growing in the existing col-
lection centres. Other issues affecting BSM is using the in-
gredient substitutes to meet the production dateline.
Although this practice is described in the ancient trad-
itional medical textbooks, substituting the original ingredi-
ent with the other inferior ingredient is a scientific
concern for quality, safety and efficacy. Some formulations
contain as much as 35 different types of ingredients. This
makes it complex and harder to assess the quality on a
daily basis. The MSP have made good progress in the
quality control of raw materials. However, there is need to
improve the quality dimensions of manufactured prod-
ucts. There is urgent need to establish additional quality
parameters to screen the manufactured products for heavy
metals, pesticide residues, cytotoxicity, microbial limits,
parasitic infestation, biological and chemical contamin-
ation. Clinical studies are recommendable for BSM to
become an evidenced-based medicine.
Conclusions
The integration of BSM with the modern health care
system in 1967, under the command of the third king
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Jigme Dorji Wangchuk, was the foundation for quality
assurance system in Bhutan. Having received the govern-
ment’s support and wider people’s acceptance, there is
no reason for the BSM not to flourish and improve its
quality of health care services. Three functional organi-
zations including FoTM, NTMH and MSP have estab-
lished their image and brand as ‘Man-jong So-wa-rig-pa’
(often spelt as ‘smen-ljong-g.so-ba-rig-pa’) and have made
decent progress over the decades. Drungtshos and smen-
pas receive free ancient medical education and knowledge
delivered through integrated curriculum (traditional and
modern pedagogies integrated). Unlike in the past, the
traditional medical students are selected from the high
achiever’s list of School of Language and Culture Study
(ILCS) and most preferably with the science background.
Continuous training for 5 years (Drungtsho course) and
3 years (smen-pa course) supported by clinical attach-
ments to NTMH, internship at MSP, and the field works
at the collection centers prepares them to take up the
highly coveted job in the government run district hospitals
and Basic Health Units in the country.
Based on the job vacancies, the Drungtshos and smen-
pas are selected by the RCSC and are compulsorily reg-
istered with the BMHC (responsible for ensuring their
ethical, professional and skills standards). The standard
treatment guidelines, protocols and refresher course
provided by NTMH guide them/BSM practitioners in
providing quality and safe traditional health care ser-
vices. Trained in health and sanitation, reporting adverse
drug reactions, and good dispensing methods, the BSM
practitioners are equipped to handle safety problems and
work hand-in-hand with the modern doctors through
cross-referral system in ensuring overall quality of the
health services delivered through 58 TM centers.
The medicines that the BSM practitioners prescribe
are manufactured at MSP using the country’s own or-
ganic medicinal plants that grows in the pristine Hima-
layan mountains. Monitoring the quality of medicinal
plants at the sources and also in the laboratory using sci-
entific quality control parameters ensure the total quality
of the medicine manufactured. While ancient wisdom of
BSM related to quality assurance system were retained,
modern scientific studies were introduced, which made
it unique by its own standing. Quality control system at
MSP was inspired by the WHO guidelines and European
GMP. The MSP have registered 75 polyingredient for-
mulations with the DRA that regulates stringent (by
local standard) manufacturing process and quality con-
trol measures through registration and regulatory audit
in the country.
We argue that the quality control system in Bhutan
manages to reach the high standards required by mod-
ern science while retaining and integrating traditional
notions and measures of quality as enshrined by BSM.
However, many efficacy and effectiveness stories remains
anecdotal whose efficacies are based on the BSM text-
books or first-hand experience of Drungtshos. These
claims need to be substantiated by the chemical and
clinical studies, which is partially lacking at the MSP due
to limited technical experts and financial resources. The
safety and effectiveness of BSM can be substantiated
only through clinical studies and such studies can be
conducted at relatively low cost as studying traditional
medicines does not require pre-clinical nor toxicology
studies. Few studies carried out by the first author on 11
medicinal plants [57, 58] in collaborations with UOW
and JCU in Australia, and SU and BIOTEC in Thailand,
resulted in the: a) elucidation of five new phytochemi-
cals, b) verification of the ethnopharmacological uses of
these medicinal plants, and c) discovery of new antimal-
arial drug lead candidates. These scientific data form the
basis for developing plant monograph and quality con-
trol parameters with the known marker compounds.
Remaining plants can be investigated using similar strat-
egy and protocols. It is proper to first focus on the
scientific studies of single ingredient. The metabolomics
involving mass Spectrometry (MS), Infrared Spectros-
copy (IRS), Gas Chromatography Mass Spectrometry
(GCMS) and Nuclear Magnetic Resonance (NMR) could
help us understand the complex chemical mixture re-
sponsible for the efficaciousness of the BSM.
Immediate attention can be given to the following: a)
focus on studying individual medicinal plants and creat-
ing metabolomics fingerprints of bioactive marker com-
pounds including HPTLC profile which can be used for
daily quality control evaluations, b) carry out advanced
molecular and clinical studies on the finished products
to substantiate the ethnopharmacological uses, c) check
the chemical and bioactivity variations between the wild
types and the cultivated species as chemical profile
would be different depending upon their nutrient avail-
ability, which could affect the quality of medicines, and
d) collaborate with other So-wa-rig-pa-practicing coun-
tries to identify existing differences and similarities in
terms of education and clinical practices, plants uses
and formulations, research and development activities,
and the quality assurance of the raw materials and fin-
ished products.
The BSM including medicinal plants program in
Bhutan is one of the sustainable vehicles of GNH. For
patients ˗ its formulations are a solace of treatment and
cure; for BTM and So-wa-rig-pa practitioners ˗ it is a
source of employment; for pharmaceutical organiza-
tions ˗ it is a potential chemotherapeutic pool waiting
for biodiscovery [59]; and for farmers ˗ it is a tool for
income generation and poverty eradication [60]. Overall,
it accelerates the health and well-being of the society and
produces happy society. Failing to maintain the quality of
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BSM would negatively affect the sustainability of the
health care system and the networks of medicinal plants
stake holders including patients, farmers, brokers, busi-
ness people and buyers, MSP, TMH, FoTM, MAPS and
the NBC. Therefore, continuous efforts to improve the
quality of BSM are essential and require immediate gov-
ernment investments in developing advance research and
development facilities.
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